| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02801799 Details | 2017-03-30 Interventional | 1 | 60 | Ropivacaine Pain, Postopera… Anaesthesia Other Acute Pos… | The trial was comprised of two parts. After the first part we could repudiate our hypothesis.
Thus, no reason to carry on with the second part of the trial. - | |||
| NCT01351792 2010-022895-30 Details | 2017-03-30 Interventional | 3 | 113 | Budesonide, For… Lung Diseases Lung Diseases, … Pulmonary Disea… Chronic Obstruc… | - - | |||
| NCT01206101 2009-013090-18 Details | 2017-03-30 Interventional | 2 | 3 | Liraglutide Diabetes Mellit… Diabetes Mellit… Diabetes | The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well
as challenges relating to trial execution and study completion. Due to the premature termination of the trial prior to islet cell transplantation in any randomised subject, no results are available. | |||
| NCT00738699 Details | 2017-03-30 Interventional | 2 | 415 | Albumin-Bound P… Farletuzumab Paclitaxel Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | study did not meet pre-specified criteria for continuation following interim futility analysis This study was prematurely terminated by the sponsor following results of the preplanned futility analysis showing the study was unlikely to meet its statistically-defined coprimary endpoints. | |||
| NCT02087241 Details | 2017-03-29 Interventional | 2 | 22 | Adavosertib Carboplatin Pemetrexed Carcinoma, Non-… Lung Neoplasms Previously Untr… | The sponsor decided to terminate the study. The study was terminated on June 1, 2015 by the sponsor. The Primary Outcome Measure (Progression Free Survival) was not assessed and the randomised portion of the study was not done. | |||
| NCT02015663 Details | 2017-03-29 Interventional | 4 | 32 | Tobramycin Cystic Fibrosis Fibrosis | - Due to premature termination, summaries and analyses planned in the protocol were eliminated in the statistical analysis plan prior to database lock. No inferential analysis will be provided. | |||
| NCT01475266 Details | 2017-03-29 Interventional | 2/3 | 51 | Apaziquone Urinary Bladder… Bladder Cancer | Sponsor's decision - | |||
| NCT00807612 Details | 2017-03-29 Interventional | 1/2 | 49 | Antibodies, Mon… Carboplatin Paclitaxel Carcinoma, Non-… Lung Neoplasms Advanced Squamo… | Study was closed due to administrative decision - | |||
| NCT01940536 Details | 2017-03-28 Interventional | 4 | 0 | Tranexamic Acid Fractures, Bone Hemorrhage Hip Fractures Blood Loss Hip Fracture | Possible change in study protocol - | |||
| NCT01589861 Details | 2017-03-28 Interventional | 1/2 | - | Lapatinib Breast Neoplasm… Breast Cancer | Data analysis - | |||
| NCT00553735 Details | 2017-03-28 Interventional | 4 | 8 | Cyclosporine Cyclosporins Lubricant Eye D… Dry Eye Syndrom… Graft vs Host D… Keratoconjuncti… Dry Eye | High number of withdrawals, appt. no-shows, or those lost to follow-up. The study was terminated early due to a high number of patients who withdrew themselves, failed to show for their appointments, or were lost to follow-up. | |||
| NCT00526643 2005-005631-97 Details | 2017-03-28 Interventional | 3 | [1 Refs] | 57 | Gemcitabine Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | scarce enrolment and presentation of positive results of similar study in June 2012. - | ||
| NCT00208403 Details | 2017-03-28 Interventional | 4 | 36 | Polymethyl Meth… Necrosis Avascular Necro… Osteoarthritis Post-traumatic … | - - | |||
| NCT00863512 Details | 2017-03-27 Interventional | 3 | 34 | Docetaxel Gemcitabine Pemetrexed Vinorelbine Carcinoma, Non-… Lung Neoplasms Lung Cancer | - - | |||
| NCT02721511 Details | 2017-03-24 Interventional | 1/2 | 0 | Furosemide Heart Failure Acute Decompens… | Investigator decision based on new device information. - | |||
| NCT01118013 Details | 2017-03-24 Interventional | 2 | 6 | Antilymphocyte … Busulfan Fludarabine Fludarabine pho… Methotrexate Mycophenolic Ac… Tacrolimus Leukemia Lymphoma Lymphoprolifera… Multiple Myelom… Myelodysplastic… Myelodysplastic… Myeloproliferat… Neoplasms Neoplasms, Plas… Plasmacytoma Preleukemia Syndrome Lymphoprolifera… Multiple Myelom… Myelodysplastic… | - - | |||
| NCT00711698 Details | 2017-03-24 Interventional | 2 | 0 | Analgesics, Opi… Anemia, Sickle … Sickle Cell Dis… Vaso-occlusive … | technical difficulties coordinating study - | |||
| NCT01564095 Details | 2017-03-23 Interventional | 2/3 | [1 Refs] | 25 | Pharmaceutical … Tacrolimus Tryptophan Ischemia Liver Diseases Reperfusion Inj… Wounds and Inju… Graft Dysfuncti… Graft Failure Ischemia Reperf… Poor Graft Qual… Terminal Liver … | Missing evidence of the effectiveness of the study medication - | ||
| NCT00609765 Details | 2017-03-23 Interventional | 2 | 1 | Bevacizumab Dexamethasone Doxorubicin Fluorouracil Ondansetron Streptozocin Endocrine Gland… Pancreatic Canc… | Development of new chemotherapy standard of care for treatment rendered the trial obsolete. This trial only enrolled one patient and was closed because of development of a new chemotherapy standard of care for treatment of this cancer which we felt rendered the trial obsolete. The trial was open for only 7 months. | |||
| NCT00176488 Details | 2017-03-23 Interventional | 2 | 31 | Epirubicin Vinorelbine Breast Neoplasm… Breast Cancer | Competing studies - |